Becton Dickinson & Co Stock Price, News & Analysis

Vicarious Surgical Inc. and D8 Holdings Corp. have reached a definitive business combination agreement, transitioning Vicarious to publicly trade under the new ticker symbol RBOT post-closing on the NYSE. This merger aims to enhance surgical efficiency and patient outcomes through Vicarious's advanced robotics technology, which provides significant cost savings compared to legacy systems. The transaction could yield up to $460 million in gross proceeds, supported by a $115 million private placement. The merger is anticipated to finalize by Q3 2021, pending D8 shareholder approval.

BD (Becton, Dickinson and Company) announced it has received 510(k) clearance from the FDA for its new Pristine™ Long-Term Hemodialysis Catheter, set to be available in the U.S. in May 2021. This innovative catheter features a unique side-hole free symmetric Y-Tip™ distal lumen design aimed at improving patient outcomes by minimizing complications such as thrombus formation. Following a feasibility study involving 45 patients, primary patency rates were reported at 100.0% at 60 days and 90.9% at 180 days, indicating promising performance for patients requiring hemodialysis.

On April 13, 2021, BD (NYSE: BDX) announced that its BD MAX™ Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay has been recognized by the WHO as part of the moderate complexity automated NAAT class for TB diagnostics. This assay allows simultaneous detection of the TB bacteria and mutations for resistance to isoniazid (INH) and rifampicin (RIF). BD emphasizes its commitment to combating antimicrobial resistance and improving TB treatment, marking a significant milestone for the product. The BD MAX™ system is already CE marked and available in Europe and beyond.

BD (Becton, Dickinson and Company) (NYSE: BDX) will announce its financial results for Q2 of fiscal year 2021 on May 6, 2021, at approximately 6:00 a.m. ET. The results will be shared via a press release and presentation materials on its investors' website. Following this, a conference call will be held at 8:00 a.m. ET, and can be accessed through a dedicated telephone line. The webcast will be available for replay until May 13, 2021.

BD (Becton, Dickinson and Company) is set to invest $65 million in a new 120,000 square-foot facility in Tucson, Arizona, aimed at enhancing its supply chain capabilities. The facility will serve as a final-stage manufacturing and sterilization center, expected to be operational by mid-2022, and create approximately 40 new jobs. BD's initiative is projected to generate a $122 million economic impact over the next decade, reinforcing the company's commitment to public health and operational efficiency.

On April 1, 2021, BD (Becton, Dickinson and Company) announced that the FDA granted Emergency Use Authorization (EUA) for its rapid antigen test, the BD Veritor™ Plus System, to screen asymptomatic individuals for SARS-CoV-2 through serial testing. This authorization allows testing twice over two to three days, enhancing the detection of COVID-19 and supporting efforts to return to normalcy. The system facilitates testing in various settings like schools and workplaces, addressing public health reporting challenges through a collaboration with ImageMover for efficient data management.

BD (Becton, Dickinson and Company) announces that the FDA has granted emergency use authorization (EUA) for a rapid antigen test capable of detecting SARS-CoV-2, influenza A, and influenza B in a single test. The BD Veritor™ Plus System test will be available this summer, enabling healthcare providers to distinguish between these viral infections quickly. The test delivers results in about 15 minutes, streamlining the diagnostic process during the flu season. BD currently has over 70,000 active testing systems across multiple healthcare settings.

BD (Becton, Dickinson and Company) has partnered with ImageMover to launch a mobile app that enhances the reporting of SARS-CoV-2 antigen testing results from the BD Veritor™ Plus System. This app aims to simplify data collection at everyday settings like schools and businesses, addressing the challenges of managing test subject demographics and reporting. Available immediately, the ImageMover app provides secure, automated reporting to health authorities, streamlining the process for organizations lacking sophisticated IT infrastructure. The partnership supports BD's innovation in COVID-19 testing solutions.

BD (Becton, Dickinson and Company) has acquired GSL Solutions, Inc., a company specializing in smart medication devices that enhance the security and efficiency of medication storage and compliance. This acquisition aims to bolster BD's medication management capabilities in retail pharmacies and outpatient settings. BD sees this as a strategic move to address growing market demands for automated tracking of medications. GSL's technology includes RFID-based systems that improve operational efficiency and reduce patient wait times. The transaction is expected to be immaterial financially.